Mr. Speaker, we know that we have a lot to learn from the ways that other jurisdictions have dealt with exactly these issues, particularly, around importation and around how we know that what is on the label is really what is in the product and for that we also need resources. We have learned from the FDA in the United States that it may not be able to inspect even 1% of the drugs that come into that country.
I thank the member very much for raising these issues around counterfeit products and labelling. If the member has any suggestions of witnesses who should come before the committee, we would very much like to hear from any of the stakeholders that he has heard from who are concerned. We will do our best to make this bill as good as it can be.